Cargando…
Quality of life worsened the most severely in patients immediately after intensity-modulated radiotherapy for prostate cancer
PURPOSE: The aim of this study was to evaluate the chronological changes in lower urinary tract symptoms (LUTSs), disease-related quality of life (QOL), and health-related QOL (HR-QOL) of patients who received intensity-modulated radiotherapy (IMRT). PATIENTS AND METHODS: In 121 patients who had rec...
Autores principales: | Nakai, Yasushi, Tanaka, Nobumichi, Anai, Satoshi, Miyake, Makito, Asakawa, Isao, Morizawa, Yosuke, Hori, Shunta, Torimoto, Kazumasa, Fujii, Tomomi, Hasegawa, Masatoshi, Fujimoto, Kiyohide |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove Medical Press
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6203165/ https://www.ncbi.nlm.nih.gov/pubmed/30425973 http://dx.doi.org/10.2147/RRU.S168651 |
Ejemplares similares
-
The impact of the definition of biochemical recurrence following salvage radiotherapy on outcomes and prognostication in patients with recurrent prostate cancer after radical prostatectomy: a comparative study of three definitions
por: Miyake, Makito, et al.
Publicado: (2019) -
Oncological outcome, complications, lower urinary tract symptoms, and health-related quality of life after low-dose-rate salvage brachytherapy for recurrent prostate cancer following primary radiotherapy: a report of 8 cases
por: Miyake, Makito, et al.
Publicado: (2017) -
Quality of life in patients who underwent (125)I brachytherapy, (125)I brachytherapy combined with three-dimensional conformal radiation therapy, or intensity-modulated radiation therapy, for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019) -
Assessment of lower urinary symptom flare with overactive bladder symptom score and International Prostate Symptom Score in patients treated with iodine-125 implant brachytherapy: long-term follow-up experience at a single institute
por: Miyake, Makito, et al.
Publicado: (2017) -
Analysis of quality of life after randomized controlled trial of alpha-1 adrenoceptor antagonist alone and in combination with cyclooxygenase-2 inhibitor in patients who underwent low-dose-rate brachytherapy for prostate cancer
por: Nakai, Yasushi, et al.
Publicado: (2019)